Oxandrolone

Generic Name: Oxandrolone

Brand Names: Oxandrin

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₃₀O_₃

CAS Number: 53-39-4

Unique Ingredient Identifier: 7H6TM3CT4L

Background: A synthetic hormone with anabolic and androgenic properties.

Indication: Use to promote weight gain after weight loss following extensive surgery.

Associated Conditions: Amino acid catabolism disorder, Pain

Associated Therapies: Weight Gain

Clinical Trials

Oxandrolone for the Treatment of Bone Marrow Aplasia in Fanconi Anemia

Phase 1

Completed

Conditions: Fanconi Anemia

Interventions: Drug: Oxandrolone

First Posted Date: 2005-10-24

Last Posted Date: 2011-07-15

Lead Sponsor: Children's Hospital Medical Center, Cincinnati

Target Recruit Count: 10

Registration Number: NCT00243399

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

The Use of Anabolic Steroids to Improve Function After Spinal Cord Injury

Not Applicable

Completed

Conditions: Spinal Cord Injury

First Posted Date: 2005-09-22

Last Posted Date: 2008-02-13

Lead Sponsor: US Department of Veterans Affairs

Target Recruit Count: 40

Registration Number: NCT00223769

Locations: 🇺🇸
Miami Veterans Affairs Medical Center, Miami, Florida, United States

Oxandrolone to Heal Pressure Ulcers

Phase 3

Terminated

Conditions: Pressure Ulcer

Interventions: Drug: Placebo
Drug: Oxandrolone

First Posted Date: 2005-01-10

Last Posted Date: 2013-12-20

Lead Sponsor: US Department of Veterans Affairs

Target Recruit Count: 212

Registration Number: NCT00101361

Locations: 🇺🇸
VA Medical Center, Miami, Miami, Florida, United States
🇺🇸
VA San Diego Healthcare System, San Diego, San Diego, California, United States
🇺🇸
Zablocki VA Medical Center, Milwaukee, Milwaukee, Wisconsin, United States

and more 13 locations

Study of Albuterol and Oxandrolone in Patients With Facioscapulohumeral Dystrophy (FSHD)

Not Applicable

Completed

Conditions: Muscular Dystrophies

First Posted Date: 2001-12-07

Last Posted Date: 2015-03-25

Lead Sponsor: FDA Office of Orphan Products Development

Target Recruit Count: 160

Registration Number: NCT00027391

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Nutrition Intervention in AIDS Wasting

Phase 4

Completed

Conditions: HIV Wasting Syndrome

First Posted Date: 2000-08-09

Last Posted Date: 2010-01-13

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registration Number: NCT00006167

Locations: 🇺🇸
Tufts University School of Medicine, Boston, Massachusetts, United States

The Effects of Hormones in Growth Hormone-Treated Girls With Turner Syndrome

Phase 2

Completed

Conditions: Dwarfism
Turner's Syndrome

First Posted Date: 1999-11-04

Last Posted Date: 2017-07-02

Lead Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Target Recruit Count: 80

Registration Number: NCT00001343

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Oxandrolone Compared With a Placebo on Growth Rate in Girls With Growth Hormone-Treated Turner's Syndrome

Phase 2

Completed

Conditions: Turner's Syndrome

First Posted Date: 1999-10-19

Last Posted Date: 2008-09-10

Lead Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Target Recruit Count: 80

Registration Number: NCT00004275

Locations: 🇺🇸
Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy